Literature DB >> 21451396

Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients.

Ming Y Lim1, Rajiv K Pruthi.   

Abstract

With increasing longevity, the prevalence of cardiovascular disease (CVD) risk factors in hemophilia patients is expected to increase; however, evidence-based guidelines on management are lacking. The aim of the study was to determine the prevalence and management of CVD risk factors in hemophilia patients. A retrospective study of 58 adult hemophilia patients (≥35 years) attending Mayo Comprehensive Hemophilia Center between 1 January 2006 and 15 October 2009 were reviewed. The prevalence of CVD risk factors was hypertension 65.5%, diabetes 10.3%, smoking 12.5% and obesity 19.6%. A total of 31% did not have a lipid profile on record. Management of risk factors included antihypertensive medications in 84.2% and lipid-lowering agents in 12.1%. During their medical evaluation, four of seven active smokers received smoking cessation counseling and four of 11 obese patients received lifestyle modification advice. Eight patients (13.8%) experienced a CVD event: myocardial infarction (MI) (n=3), coronary artery disease (n=2), both MI and ischemic stroke (n=1) and hemorrhagic strokes (n=2). Only five of eight patients were on low-dose aspirin, of which aspirin was discontinued in one patient after he was diagnosed with hemophilia following a bleeding work-up. Another patient on dual antiplatelet therapy post stent placement developed epistaxis resulting in clopidogrel cessation. Hemophilia patients are at risk for CVD, similar to the general age-matched male population. Screening for CVD risk factors, with preventive dietary and pharmacologic interventions, play a key role in the prevention and long-term management of CVD. Collaborative efforts between primary care providers, cardiologists and hemophilia center specialists remain essential in managing these complex patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21451396     DOI: 10.1097/MBC.0b013e328345f582

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  9 in total

Review 1.  Acute coronary syndrome in patients with hemophilia: a delicate balancing act.

Authors:  Jacob J Mayfield; Andrew D Leavitt; Talha Tanriverdi; Krishan Soni; Thomas A Ports; M Roselle Abraham
Journal:  J Thromb Thrombolysis       Date:  2022-05-11       Impact factor: 5.221

2.  Discrepant ratios of arterial versus venous thrombosis in hemophilia A as compared with hemophilia B.

Authors:  Antonio Girolami; Irene Bertozzi; Giulia Berti de Marinis; Valentina Tasinato; Luisa Sambado
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

3.  High prevalence of overweight/obesity in adult persons with hemophilia in Utah and a review of the literature.

Authors:  Ming Y Lim; Guo Wei; Angela P Presson; Paul Bray; George M Rodgers
Journal:  Blood Coagul Fibrinolysis       Date:  2020-12       Impact factor: 1.276

Review 4.  Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.

Authors:  Victor A Ferraris; Leonard I Boral; Alice J Cohen; Susan S Smyth; Gilbert C White
Journal:  Cardiol Rev       Date:  2015 Mar-Apr       Impact factor: 2.644

Review 5.  Comorbidities of cardiovascular disease and cancer in hemophilia patients.

Authors:  Jiaan-Der Wang
Journal:  Thromb J       Date:  2016-10-04

6.  A second retrospective database analysis confirms prior findings of apparent increased cardiovascular comorbidities in hemophilia A in the United States.

Authors:  Thomas J Humphries; Alice Ma; Craig M Kessler; Rajesh Kamalakar; Jennifer Pocoski
Journal:  Am J Hematol       Date:  2016-04-07       Impact factor: 10.047

7.  Prevalence of cardiovascular diseases and risk factors in adult patients with haemophilia: a cross-sectional study in a tertiary care hospital clinic in Sri Lanka.

Authors:  Thamudika Vithanage; Visaka Ratnamalala; Chandana Wickramaratne; Gaya Katulanda; Chithramali Hasanthika Rodrigo
Journal:  BMC Cardiovasc Disord       Date:  2022-07-30       Impact factor: 2.174

8.  BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years.

Authors:  Johnny Mahlangu; Maria Fernanda Lopez Fernandez; Elena Santagostino; Shadan Lalezari; Despina Tseneklidou-Stoeter; Horst Beckmann; Nikki Church
Journal:  Eur J Haematol       Date:  2020-03-23       Impact factor: 2.997

9.  The SLIM study-Shared medical appointments to change lifestyles of overweight people with haemophilia: A randomized multiple baseline (n-of-1) design.

Authors:  Marcel A L Hendriks; Johanna W M van Wanroij; Britta A P Laros-van Gorkom; Maria W G Nijhuis-van der Sanden; Thomas J Hoogeboom
Journal:  Haemophilia       Date:  2021-05-04       Impact factor: 4.287

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.